Outlook Therapeutics (OTLK) Competitors $1.20 -0.01 (-0.83%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$1.22 +0.02 (+1.67%) As of 04/4/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock OTLK vs. IVA, FDMT, IKT, TNGX, KOD, CGC, PBYI, DBVT, PRQR, and HURAShould you be buying Outlook Therapeutics stock or one of its competitors? The main competitors of Outlook Therapeutics include Inventiva (IVA), 4D Molecular Therapeutics (FDMT), Inhibikase Therapeutics (IKT), Tango Therapeutics (TNGX), Kodiak Sciences (KOD), Canopy Growth (CGC), Puma Biotechnology (PBYI), DBV Technologies (DBVT), ProQR Therapeutics (PRQR), and TuHURA Biosciences (HURA). These companies are all part of the "pharmaceutical products" industry. Outlook Therapeutics vs. Inventiva 4D Molecular Therapeutics Inhibikase Therapeutics Tango Therapeutics Kodiak Sciences Canopy Growth Puma Biotechnology DBV Technologies ProQR Therapeutics TuHURA Biosciences Outlook Therapeutics (NASDAQ:OTLK) and Inventiva (NASDAQ:IVA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment, community ranking and earnings. Is OTLK or IVA more profitable? Company Net Margins Return on Equity Return on Assets Outlook TherapeuticsN/A N/A -225.12% Inventiva N/A N/A N/A Does the media favor OTLK or IVA? In the previous week, Inventiva had 6 more articles in the media than Outlook Therapeutics. MarketBeat recorded 6 mentions for Inventiva and 0 mentions for Outlook Therapeutics. Outlook Therapeutics' average media sentiment score of 0.00 beat Inventiva's score of -0.04 indicating that Outlook Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Outlook Therapeutics Neutral Inventiva Neutral Which has more volatility and risk, OTLK or IVA? Outlook Therapeutics has a beta of 0.47, suggesting that its stock price is 53% less volatile than the S&P 500. Comparatively, Inventiva has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500. Which has preferable valuation and earnings, OTLK or IVA? Outlook Therapeutics has higher earnings, but lower revenue than Inventiva. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOutlook TherapeuticsN/AN/A-$75.37M-$7.42-0.16Inventiva$9.20M17.52-$119.51MN/AN/A Do analysts recommend OTLK or IVA? Outlook Therapeutics currently has a consensus price target of $10.20, indicating a potential upside of 750.00%. Inventiva has a consensus price target of $12.00, indicating a potential upside of 290.88%. Given Outlook Therapeutics' higher possible upside, analysts plainly believe Outlook Therapeutics is more favorable than Inventiva.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Outlook Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Inventiva 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Does the MarketBeat Community prefer OTLK or IVA? Outlook Therapeutics received 141 more outperform votes than Inventiva when rated by MarketBeat users. However, 82.76% of users gave Inventiva an outperform vote while only 71.12% of users gave Outlook Therapeutics an outperform vote. CompanyUnderperformOutperformOutlook TherapeuticsOutperform Votes16571.12% Underperform Votes6728.88% InventivaOutperform Votes2482.76% Underperform Votes517.24% Do insiders and institutionals hold more shares of OTLK or IVA? 11.2% of Outlook Therapeutics shares are held by institutional investors. Comparatively, 19.1% of Inventiva shares are held by institutional investors. 4.8% of Outlook Therapeutics shares are held by insiders. Comparatively, 32.0% of Inventiva shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. SummaryInventiva beats Outlook Therapeutics on 9 of the 13 factors compared between the two stocks. Remove Ads Get Outlook Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OTLK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OTLK vs. The Competition Export to ExcelMetricOutlook TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$38.42M$2.83B$5.26B$7.12BDividend YieldN/A1.53%4.89%4.08%P/E Ratio-0.1630.2421.3817.51Price / SalesN/A420.30355.0688.78Price / CashN/A168.6838.1834.64Price / Book-0.763.486.233.79Net Income-$75.37M-$72.06M$3.21B$247.48M7 Day Performance-9.09%-12.89%-8.47%-6.79%1 Month Performance-20.00%-22.10%-4.87%-11.53%1 Year Performance-87.04%-34.52%2.54%-7.82% Outlook Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OTLKOutlook Therapeutics0.9907 of 5 stars$1.20-0.8%$10.20+750.0%-87.4%$38.42MN/A-0.1620IVAInventiva1.659 of 5 stars$2.95+1.2%$12.60+327.8%-16.1%$154.55M$15.62M0.00100Analyst ForecastNews CoverageFDMT4D Molecular Therapeutics2.059 of 5 stars$3.24-10.9%$30.63+846.7%-90.0%$151.64M$37,000.00-1.15120Gap DownIKTInhibikase Therapeutics1.1732 of 5 stars$2.18-5.0%$6.50+198.9%-16.4%$150.86M$260,000.00-0.816News CoverageGap DownTNGXTango Therapeutics1.8504 of 5 stars$1.39-5.8%$12.33+790.5%-83.4%$149.73M$42.07M-1.1790Positive NewsKODKodiak Sciences3.96 of 5 stars$2.82-3.0%$8.00+183.3%-42.4%$148.14MN/A-0.7790Analyst RevisionNews CoverageGap DownCGCCanopy Growth1.7322 of 5 stars$0.93-5.6%$2.00+115.1%-90.6%$147.51M$276.75M-0.243,150PBYIPuma Biotechnology4.0401 of 5 stars$2.95-6.2%$7.00+137.7%-47.4%$145.61M$230.47M6.11200Positive NewsGap DownDBVTDBV Technologies3.1775 of 5 stars$7.10+14.5%$22.50+216.9%-5.9%$143.80M$15.73M-1.5580Gap DownHigh Trading VolumePRQRProQR Therapeutics1.366 of 5 stars$1.34-4.6%$9.50+611.6%-45.9%$140.46M$18.91M-4.17180Gap DownHURATuHURA BiosciencesN/A$3.29-6.9%$13.00+295.7%N/A$139.12MN/A0.00N/AAnalyst ForecastAnalyst RevisionNews CoveragePositive NewsGap Down Remove Ads Related Companies and Tools Related Companies Inventiva Competitors 4D Molecular Therapeutics Competitors Inhibikase Therapeutics Competitors Tango Therapeutics Competitors Kodiak Sciences Competitors Canopy Growth Competitors Puma Biotechnology Competitors DBV Technologies Competitors ProQR Therapeutics Competitors TuHURA Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OTLK) was last updated on 4/5/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Outlook Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Outlook Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OTLK Stock Free OTLK Stock Alerts